Chojnowska-Jezierska J, Jabłoński S, Tkaczewski W
III Klinika Chorób Wewnetrznych WAM.
Wiad Lek. 1993 May;46(9-10):332-6.
Hypolipaemic effectiveness and unfavourable effects of acipimox and fenofibrate were evaluated in patients with essential hyperlipoproteinaemia type II. The studies were carried out in two groups of 30 patients each. The studied patients were treated for three months with diet, and for another three months one group received acipimox (750 mg/day), and the other group was given fenofibrate (300 mg/day). After three months of pharmacological treatment in both groups a statistically significant decrease was seen of the concentrations of total cholesterol (by 13.8% and 19.3% respectively), LDL cholesterol (by 16.3% and 22.1%). TG (by 22.7% and 28.9%). The increase of HDL cholesterol concentration (twofold increase after fenofibrate) was non-significant. Desired LDL cholesterol values were achieved in eight patients (26.7%) treated with fenofibrate and in two patients (6.6%) receiving acipimox. Both drugs were well tolerated. Unfavourable effects were slight and did not require drug withdrawal.
对患有II型原发性高脂蛋白血症的患者评估了阿西莫司和非诺贝特的降血脂效果及不良反应。研究在两组患者中进行，每组30人。研究对象先接受了三个月的饮食治疗，之后又进行了三个月的治疗，其中一组服用阿西莫司（750毫克/天），另一组服用非诺贝特（300毫克/天）。经过三个月的药物治疗后，两组患者的总胆固醇浓度（分别下降了13.8%和19.3%）、低密度脂蛋白胆固醇（分别下降了16.3%和22.1%）、甘油三酯（分别下降了22.7%和28.9%）均出现了统计学上的显著下降。高密度脂蛋白胆固醇浓度的升高（非诺贝特治疗后升高了两倍）并不显著。接受非诺贝特治疗的患者中有8人（26.7%）达到了理想的低密度脂蛋白胆固醇值，接受阿西莫司治疗的患者中有2人（6.6%）达到了该值。两种药物的耐受性都很好。不良反应轻微，无需停药。
